Last reviewed · How we verify

NCT03178825

Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause

Completed NA Last updated 11 August 2020
What this trial tests

NA trial testing Hybrid Fractional Laser in Vaginal Atrophy in 60 participants. Completed in 25 February 2020.

Timeline
19 May 2017
Primary endpoint
25 February 2020
25 February 2020

Quick facts

Lead sponsorSciton
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date19 May 2017
Primary completion25 February 2020
Estimated completion25 February 2020
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Sciton

Who can join

Adults 40 to 70, female only, with Vaginal Atrophy or Sexual Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 nm lasers for treatment of symptoms of Genitourinary Syndrome of Menopause.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Hybrid Fractional Laser

Trials testing the same drug.

Other recruiting trials for Vaginal Atrophy

Currently open trials in the same condition.

Other Sciton trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03178825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing